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ABSTRACT The aim of this study was to determine distribu-
tion of the Candida (C.) species in onychomycosis and anal-
yses in vitro susceptibility to fluconazole and itraconazole. 
In recent years, cases of onychomycosis in Lithuania caused 
by Candida have increased significantly. In the period be-
tween 2009 and 2016, a total of 8149 clinical cases (outpa-
tients and inpatients) were investigated at the Vilnius Uni-
versity Hospital Santaros Clinics (VUH SC). Candida yeasts 
were identified using VITEK 2 (BioMerieux, France) and IVD 
Maldi biotyper 2.3 (Bruker Daltonik GmbH, Germany), auto-
mated systems for identification of yeasts. The antifungal 
susceptibility to the Candida species were determined by 
disc diffusion. Candida spp. were the most frequently iso-
lated pathogens in onychomycosis during the investigation 
period. The main species in onychomycosis were C. albicans 
(38.6%), followed by C. krusei (33.7%), C. tropicalis (11.1%), C. 
parapsilosis (7.9%), and other Candida (8.7%). The different 
antifungal susceptibility patterns among Candida species 
confirm the need to perform antifungal susceptibility in vi-
tro testing of yeasts from patients with onychomycosis.
KEY WORDS: onychomycosis, prevalence, Candida, anti-
fungal agents
INTRODUCTION
Derived from the Greek words “Onychos” (mean-
ing nail) and “Mykēs” (fungus), onychomycosis is a 
term that describes fungal infections of the finger-
nails and/or toenails. It is caused by different types 
of fungi, and the affected nails become brittle, thin, 
disfigured, and dichromic (1-5). The literature avail-
able on the epidemiology of onychomycosis is var-
ied. Onychomycosis accounts for approximately 50% 
of all nail fungal infections and affects 2.0-18.5% or 
more of the world’s population (6-7). The reported 
prevalence of onychomycosis is up to 14% in North 
America, 20% in East Asia, and 26.8% in Europe (8). 
Epidemiology of infectious Candida (C.) species was 
not well documented in Lithuania. Several studies 
have reported the prevalence of Candida species in 
dermatomycosis and onychomycosis (9-11).
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Candida yeast morphology was examined from 
cultures grown on yeast morphology agar (Difco, 
USA) for two days at 25 °C. The cultures were exam-
ined microscopically using a Leica DM 5000B with 
differential interference contrast microscopy (×1000 
magnification) and a digital camera, Leica DFC 450 
(Leica Microsystems, Germany).
The Neo-Sensitabs (Rosco Diagnostica, Taastrup, 
Denmark) and Mast (MAST DIAGNOSTICA, Germany) 
discs were used in this study. To determine the anti-
fungal susceptibility patterns of Candida spp., a disk of 
each antifungal drug, including fluconazole FLU (25 
µg/disk) and itraconazole ITR (10 µg/disk), were used. 
Disk diffusion assay and the interpretation of results 
were performed according to the manufacturer’s in-
structions and M44-A2 guidelines for yeasts (15-17).
The data were presented as absolute numbers 
and percentages. The prevalence of Candida yeasts in 
onychomycosis, as well as changes in their suscepti-
bility to fluconazole and itraconazole, were calculated 
using a linear model and determination coefficient, 
R2. The minimum significance level was set at P<0.05.
All statistical analyses were performed with Statis-
tica for Windows ver. 6.0 software 18 (18).
RESULTS
Among the 8149 clinically suspected cases of ony-
chomycosis, 4229 (51.89%) patients were confirmed 
to be affected with onychomycosis. The positive rate 
percentage among all patients examined during the 
study period was in the range 43.32% to 66.05%. A 
total 4229 onychomycosis causative agents were iso-
lated and identified during investigation period. The 
isolated causative agents were classified into three 
groups: yeasts, dermatophytes, and non-dermato-
phytes fungi. In our study, Candida yeasts were found 
to be the most frequent causative agents of onycho-
mycosis (detected in 2044 patients, 48.33%), followed 
by dermatophytes (1461, 34.55%) and non-dermato-
phytes (724, 17.12%).
The genus Candida is one of the most prominent 
causes of onychomycosis around the world and the 
Candida species are considered one of the most im-
portant causes of fingernail onychomycosis, espe-
cially in women. Candida albicans is the most preva-
lent species, followed by C. glabrata, C. parapsilosis, C. 
tropicalis, C. lusitaniae, and C. krusei (5,12).
Treatment of onychomycosis is necessary, often 
prolonged, and is associated with potential adverse 
drug reactions; this infection can also affect quality 
of life and can lead to a secondary infection if left un-
treated (4,8). The approved treatment strategies to 
deal with onychomycosis involve the use of topical, 
oral, and combination therapy (3,13). Itraconazole 
and fluconazole are the most widely available anti-
fungal agents used for systemic treatment of onycho-
mycosis (14).
The aim of this study was to determine Candida 
species distribution in onychomycosis and analyze 
in vitro susceptibility to fluconazole and itraconazole 
during the period from 2009 to 2016 in Lithuania.
PATIENTS AND METHODS
Between 2009 and 2016, a total of 8149 outpa-
tients and inpatients with clinical suspicion of ony-
chomycosis were investigated at the Vilnius Univer-
sity Hospital Santaros Clinics (VUH SC). The inves-
tigation was performed at the Laboratory of Micro-
biology of the Centre of Laboratory Medicine, VUH 
SC, and the Nature Research Centre. The specimens 
were obtained from clinically abnormal nails. The 
pathological material (nail fragments) was plated on 
Sabouraud Agar containing chloramphenicol (Oxoid, 
England), dermatophyte (DTM) agar (Liofilchem, Ita-
ly), and corn meal agar (Sifin diagnostics Gmbh, Ger-
many) and cultivated in an incubator for 3-14 days at 
a temperature of 28±2 °C. Candida yeasts were identi-
fied using VITEK 2 (BioMerieux, France) and IVD Maldi 
biotyper 2.3 (Bruker Daltonik GmbH, Germany), auto-
mated systems for identification of yeasts.
Figure 1. Distribution of main Candida species in onychomycosis.
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A total of 16 Candida species were identified from 
the patients’ material. Among Candida yeasts, the 
most commonly isolated organisms were C. albicans 
(n=789; 38.6%) followed by C. krusei (Issatchenkia ori-
entalis) (n=688; 33.7%), C. tropicalis (n=226; 11.1%), 
and C. parapsilosis (n=162; 7.9%) (Figure 1). Account-
ing for 8.7%, other species from this genus were C. 
glabrata, C. famata (Debaryomyces hansenii), C. lusita-
niae (Clavispora lusitaniae), C. zeylanoides, C. guillier-
mondii (Meyerozyma guilliermondii), C. intermedia, C. 
apicola, C. pelliculosa (Wickerhamomyces anomalus), 
C. lambica, C. rugosa (Diutina rugosa), C. duobushae-
mulonis, and C. sphaerica (Kluyveromyces lactis). The 
current valid taxonomic denominations for genera 
and species were listed in parallel to the reported 
species names (19-20).
Analyzing the results over time, we found a highly 
significant change in the pattern of the isolated Can-
dida species, with C. krusei predominating in the first 
five study years (2009-2013) (R2 = 0.72, P=0.0076) 
and C. albicans over the 2014-2016 period (R2 = 0.60, 
P=0.0237). Over the eight-year period, C. tropicalis 
isolation rate increased (with the exception of the 
2011-2013period), though no significant difference 
was observed (R2 = 0.3915, P=0.0979). C. parapsilosis 
was detected only in two or three cases during the 
2009-2011period. There was also an upward trend in 
the number of C. parapsilosis from 2012 to 2013, a de-
crease in 2014, and an increase over the 2015-2016 
period (R2 = 0.4149, P=0.0852). Other species from 
this genus (C. intermedia, C. pelliculosa, C. rugosa, C. 
duobushaemulonis, C. sphaerica, C. apicola, C. famata, 
C. guilliermondii, C. lusitaniae, C. zeylanoides, and C. 
glabrata) were isolated only in a small number of cas-
es of onychomycosis, and no significant differences 
were observed in their prevalence (P>0.05).
Figure 2 and Figure 3 summarize the in vitro sus-
ceptibility of 1155 Candida isolates to fluconazole and 
969 Candida isolates to itraconazole as determined 
by disk diffusion testing. Analyzing the results over 
time, we found a highly significant change in the pat-
tern of Candida yeasts susceptible to fluconazole (R2 
= 0.5994, P=0.0244) and resistant to fluconazole (R2 
= 0.7904, P=0.0031). However, the differences among 
Candida yeasts with intermediate sensitivity to flu-
conazole were not statistically significant (R2 = 0.41, 
P=0.0839). The number of Candida yeasts susceptible 
to fluconazole gradually increased – a significant dif-
ference was observed from 2009 to 2015 (R2 = 0.71, 
P=0.0141). These results probably depend on the 
distribution of species. The rate of C. albicans yeasts 
susceptible to fluconazole isolation significantly in-
creased over the eight-year period, while a significant 
decrease was observed in C. krusei yeasts resistant to 
fluconazole.
No significant difference was observed among C. 
albicans isolates (resistant – R2 = 0.06, P=0.5714; inter-
mediate – R2 = 0.16, P=0.3199; susceptible – R2 = 0.07, 
P=0.5358). The differences among C. krusei yeasts sus-
ceptible to fluconazole and those resistant to flucon-
azole were not statistically significant (resistant – R2 
= 0.17, P=0.3002; susceptible – R2 = 0.29, P=0.1713), 
but a significant difference was observed (R2 = 0.61, 
P=0.0456) in the proportion of C. krusei isolates inter-
mediately sensitive to fluconazole. During the eight-
year period, the isolation rate of C. parapsilosis yeasts 
was irregular, and therefore no significant difference 
was observed (P>0.05). A statistically significant dif-
ference was established in C. tropicalis yeasts resistant 
to fluconazole and intermediately sensitive to fluco-
nazole: resistant – R2 = 0.62, P=0.0208, intermediate 
– R2 = 0.50, P=0.0490. However, no significant differ-
ence was observed in the isolation rate increase of C. 
tropicalis yeasts susceptible to fluconazole (R2 = 0.20, 
P=0.2682).
The susceptibility of Candida yeasts to itracon-
azole is presented in Figure 3. Analyzing the suscep-
tibility to itraconazole results over time, a significant 
Figure 2. The susceptibility of Candida yeasts to fluconazole.
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increase in Candida yeasts susceptible to itraconazole 
(R2 = 0.51, P=0.0481) was observed, along with a sig-
nificant decrease in Candida yeasts intermediately 
sensitive to itraconazole (R2 = 0.61, P=0.0225). How-
ever, no significant difference was observed in the de-
crease of Candida yeasts resistant to itraconazole (R2 
= 0.41, P=0.0912). There was an increase in the num-
ber of Candida yeasts susceptible to itraconazole in 
2014, coinciding with the period that C. albicans were 
the most frequent species in onychomycosis. During 
the eight-year period, no significant differences were 
observed in the decrease in the number of C. albicans 
yeasts with intermediate itraconazole sensitivity (R2 
= 0.85, P=0.0011), or those that were resistant (R2 = 
0.07, P=0.5249), and susceptible (R2 = 0.17, P=0.3199) 
to itraconazole. The in vitro susceptibility results of C. 
krusei yeasts were not statistically significant (resis-
tant – R2 = 0.27, P=0.1833; intermediate – R2 = 0.02, 
P=0.7439; susceptible – R2 = 0.39, P=0.0930). There 
were no significant differences in the in vitro suscep-
tibility results of C. parapsilosis yeasts (P>0.05), which 
were probably related to the variability of the isola-
tion rate of C. parapsilosis yeasts over the eight-year 
period. In addition, statistically significant differences 
were established in the decrease of C. tropicalis yeasts 
intermediately sensitive (R2 = 0.62, P=0.0208) and re-
sistant (R2 = 0.50, P=0.0490) to itraconazole. However, 
no significant difference was observed in the increase 
of C. tropicalis yeasts susceptible to itraconazole (R2 = 
0.20, P=0.2682).
DISCUSSION
Onychomycosis is a major problem in dermatol-
ogy due to its widespread occurrence. Its prevalence 
has increased since World War I, and today onycho-
mycosis is considered a “disease of civilization”, char-
acterized by extreme chronicity and resistance to 
therapy (21). In this study, we performed the first 
large-scale surveillance study of the distribution 
of Candida species in Lithuania. We examined 8149 
outpatients and inpatients that were suspected of 
having onychomycosis between 2009 and 2016. Ony-
chomycosis caused by Candida yeasts was confirmed 
in 48.33% of patients. Similar results were obtained 
in Poland (22,23), Brazil (24), Iran (25,26), and Croatia 
(27). Literature data indicates that yeasts could be 
responsible for an increase in mycosis incidents in 
recent years (23). The yeast species most frequently 
isolated from patients with onychomycosis were 
C. albicans (38.6%), followed by C. krusei (33.7%), C. 
tropicalis (11.1%), and C. parapsilosis (7.9%). Studies 
have reported that the most frequent Candida spe-
cies, especially C. albicans, C. krusei, C. tropicalis, and C. 
parapsilosis, account for most of the cases of onycho-
mycosis worldwide (6,22-28). The epidemiology and 
etiological agents of onychomycosis vary in different 
geographic areas (4,8).
Onychomycosis often has a significant impact on 
the quality of life in those patients who seek treat-
ment. Apart from cosmetic problems, the disorder 
may result in pain while walking as well as difficulties 
in nail cutting and finding suitable footwear (29,30).
Not many studies in Lithuania have focused on the 
susceptibility of Candida spp., which are responsible 
for onychomycosis (31). Candida yeasts are morpho-
logically, physiologically, and genetically specialized. 
There is a possibility that the causative agents of ony-
chomycosis could soon become resistant to one or 
more antifungal agents. Itraconazole and fluconazole 
are the most widely available antifungal agents used 
for the systemic treatment of onychomycosis (13).
In our study, the pattern of C. albicans susceptibility 
to fluconazole was as follows: the majority of isolates 
(68.3%) were susceptible, while 18.8% of isolates were 
intermediately sensitive, and 12.9% were resistant. 
In vitro susceptibility testing of fluconazole demon-
strated that resistance to fluconazole in C. parapsilosis 
and C. tropicalis was 31.3% and 25.9%, respectively. 
Figure 3. The susceptibility of Candida yeasts to itraconazole.
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During the eight-year period, resistance to itracon-
azole in C. albicans isolates was 28.3%. In the present 
study, a high number of C. krusei isolates (59.0%) re-
sistant to itraconazole was found. In vitro susceptibil-
ity testing of itraconazole demonstrated that the re-
sistance to fluconazole among C. parapsilosis and C. 
tropicalis was 38.3% and 22.4%, respectively.
This tendency towards resistance has also been 
noticed by other researchers. Some have reported 
that C. krusei were genetically resistant to a certain 
antifungal drug and it was therefore recommended 
for use in treatment (32-34). Other studies have also 
reported an increasing risk of fluconazole-resistant 
Candida yeasts (35,36).
Today, the increase in tourism and immigration 
has influenced the distribution of some species and 
can quickly change the epidemiological profile in a 
given geographical area. We think that culture testing 
and the identification of pathogens with susceptibil-
ity testing are important steps in helping clinicians 
choose the correct therapy to treat onychomycosis.
CONCLUSION
In the period between 2009 and 2016, Candida 
yeasts were found to be the most frequent causative 
agents of onychomycosis in Lithuania. C. albicans was 
the most frequently isolated species from patients 
with onychomycosis. Candida species distribution 
showed a highly significant change in the pattern of 
causative agents in onychomycosis: the isolation rate 
of C. albicans increased, while C. krusei decreased. The 
different antifungal susceptibility patterns among 
Candida species confirm the need to perform anti-
fungal susceptibility in vitro testing of yeasts from pa-
tients with onychomycosis.
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